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Abstract
Background: Decidualization (differentiation) of the endometrial stromal cells during the secretory phase of the menstrual
cycle is essential for successful implantation. Transforming Growth Factor b1 (TGFb1) canonically propagates its actions via
SMAD signalling. A role for TGFb1 in decidualization remains to be established and published data concerning effects of
TGFb1 on markers of endometrial decidualization are inconsistent.
Methodology/Principal Findings: Non-pregnant endometrial stromal cells (ESC) and first trimester decidual stromal cells
(DSC) were cultured in the presence or absence of a decidualizing stimulus. Incubation of ESCs with TGFb1 (10 ng/ml)
down-regulated the expression of transcripts encoding the decidual marker proteins prolactin (PRL), insulin-like growth
factor binding protein-1 (IGFBP-1) and tissue factor (TF). TGFb1 also inhibited secretion of PRL and IGFBP-1 proteins by ESCs
and surprisingly this response preceded down-regulation of their mRNAs. In contrast, DSCs were more refractory to the
actions of TGFb1, characterized by blunted and delayed down-regulation of PRL, IGFBP-1, and TF transcripts, which was not
associated with a significant reduction in secretion of PRL or IGFBP-1 proteins. Addition of an antibody directed against
TGFb1 increased expression of IGFBP-1 mRNA in decidualised cells. Knockdown of SMAD 4 using siRNAs abrogated the
effect of TGFb1 on expression of PRL in ESCs but did not fully restore expression of IGFBP-1 mRNA and protein.
Conclusions/Significance: TGFb1 inhibits the expression and secretion of decidual marker proteins. The impact of TGFb1o n
PRL is SMAD-dependent but the impact on IGFBP1 is via an alternative mechanism. In early pregnancy, resistance of DSC to
the impact of TGFb1 may be important to ensure tissue homeostasis.
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Introduction
Decidualization, the process by which progesterone acts on the
estrogen-primed endometrium to convert precursor stromal cells
into decidual cells, is essential for successful implantation and
maintenance of pregnancy (reviewed in [1,2,3]). The decidualiza-
tion reaction is initiated in the perivascular stromal cells and under
the influence of progesterone, spreads ‘wave-like’ throughout the
stromal region. It is characterised by the phenotypic transforma-
tion of the elongated fibroblast-like endometrial stromal cells
(ESC) into a larger, spherical decidual cell. This change in cell
shape is associated with rearrangements in cellular architecture,
the accumulation of glycogen and increased expression of
prolactin (PRL) and insulin growth factor binding protein 1
(IGFBP-1) [4,5,6]. Studies using primary cultures of human
endometrial stromal cells (ESCs) have revealed that this process is
complex and likely to involve multiple factors including PGE2,
relaxin and cAMP in addition to progesterone [4,7,8,9].
A strong association exists between the degree of trophoblast
invasion and the extent of decidualization in species with a
hemochorial placenta [10]. Not only does human trophoblast
exhibit the greatest degree of trophoblast invasion observed in all
species, but also human endometrium undergoes the most
extensive decidualization reaction [11,12]. Decidualized stromal
cells are temporally and spatially positioned to promote local
homeostasis during implantation and counteract the threat of
haemorrhage during trophoblast invasion [13]. Production of
tissue factor by decidual cells is also thought to be important in
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cycle [14].
It has been hypothesised that menstruation only occurs in
species where the decidualization reaction is initiated spontane-
ously during each cycle regardless of the presence of a blastocyst
[10]. Although the classic ‘‘trigger’’ for the onset of menstruation
is the withdrawal of progesterone associated with the demise of
the corpus luteum, multiple cytokines and growth factors have
been reported to play a role in this process [15,16,17]. Based on
several lines of evidence we have previously proposed that
transforming growth factor b1( T G F b1), which canonically
transduces its signal from type II serine/threonine kinase
transmembrane receptors to the nucleus through the Sma- and
mothers against decapentaplegic (MAD)-related protein (SMAD)
signalling cascade [18], might play a role in initiating the process
of menstruation [19]. For example, expression of TGFb1i s
increased in stromal cells as they undergo decidualization [20,21].
We have previously demonstrated that treatment of decidualized
ESC with TGFb1 suppresses expression of progesterone receptor
(PR) suggesting that TGFb1 may potentiate the effects of
progesterone withdrawal[19]. In contrast, several studies have
reported that TGFb1 may increase expression of PRL in
endometrial stromal cells (ESC) [21,22].
An enhanced understanding of local mechanisms involved in
the regulation of endometrial events preceding menstruation is an
essential prerequisite for delineating the aetiology of early
pregnancy complications as well as abnormal endometrial tissue
activity associated with common gynaecological complaints such
as heavy menstrual bleeding (HMB). In the current study we have
complemented and extended our previous investigation [19] by
investigating the possibility that local production of TGFb1 within
the endometrium plays a critical role in triggering the process of
menstruation in cells from non-pregnant endometrium by
inhibiting biosynthesis and/or secretion of PRL, IGFBP-1 and
tissue factor (TF) via a SMAD-dependent pathway. We have also
examined the effects of TGFb1 in cells obtained from early
pregnancy to compare the TGFb1 response between stromal cells
decidualized in vitro and in vivo.
Materials and Methods
Patients and tissue collection
Human endometrial tissue specimens (n=20; proliferative and
secretory phase samples) were obtained from women undergoing
surgery for benign gynaecological conditions. Written informed
patient consent was provided prior to tissue collection. Local
research ethical committee approval for the study was granted.
Biopsies were collected with an endometrial suction curette
(Pipelle, Laboratoire CCD, Paris, France) or alternatively, full
thickness endometrial samples were obtained. These latter biopsies
included superficial and basal endometrium plus the endometrial-
myometrial junction. All patients were of reproductive age,
described regular menstrual cycles between 25–35 days and had
not received exogenous hormones or used an intrauterine
contraceptive device in the three months prior to surgery. All
subjects had a serum sample collected at the time of surgery for the
determination of circulating estradiol (E2) and progesterone (P)
levels by Radio Immunoassay (RIA). All samples were consistent
for the designated cycle stage based on standard histological
criteria of Noyes et al [23], the patient’s reported last menstrual
period and circulating E2 and P levels at time of biopsy collection.
Decidual tissue specimens were obtained from women (n=7; 8–
10 weeks gestation) who had undergone surgical termination of
pregnancy during the first trimester of pregnancy. All women had
an ultrasound scan to confirm viability of pregnancy and
gestational age. All material from the suction curettage procedure
was collected. Decidua parietalis tissue (n=7) was selected by
macroscopic inspection from the products of the termination
aspiration procedure and subjected to cytokeratin staining to
confirm exclusion of trophoblast. Endometrial and decidual tissue
was collected in sterile RPMI 1640 culture medium (Sigma, Poole,
Dorset, UK) and processed in one of two ways: fixed in 10%
neutral buffered formalin (NBF) 24 h at 4uC followed by storage in
70% ethanol prior to wax embedding, or used for isolation of
primary stromal cells as detailed below.
Isolation of stromal cells from non-pregnant
endometrium
Endometrial specimens (n=21) were separated into epithelial
and stromal cell preparations by enzymatic digestion as previously
described [19]. Briefly, specimens were washed in Dulbecco’s
Phosphate Buffered Saline (Sigma), minced into 1 mm
3 pieces
and digested in collagenase (1 mg/ml, Sigma) and DNAase
(0.1 mg/ml, Sigma) for 80 min at 37uC. Repeated passage
through an 18 g needle was used to aid tissue dispersion. The
tissue homogenate was re-suspended in 10 ml of RPMI 1640
medium (Sigma) and centrifuged (1700 rpm, 3 min). Cell pellets
were then re-suspended in 10 ml of RPMI 1640 medium (Sigma)
supplemented with 10% fetal calf serum (FCS) (Mycoplex, PAA
Laboratories, Kingston-Upon-Thames, UK), penicillin (50 mg/ml;
Sigma), streptomycin (50 mg/ml; Sigma) and gentamycin (5 mg/
ml; Sigma) and the stromal cells were separated from endometrial
glands by filtration through a 73 mm nylon sieve (Falcon, VWR
International Ltd, Leicestershire, UK). The filtrate, containing the
primary ESC, was plated in 75 cm
3 culture flasks (Corning
Incorporated, Corning, NY) for a minimum period of 5 days and
allowed to reach confluence.
Isolation of stromal cells from 1st trimester deciduas
All decidual samples were processed to remove both glandular
material and deplete them of CD56
bright uterine natural killer cells
(uNKs). Briefly, decidual tissue was finely minced into 1 mm
3
sections using surgical blades (Swann, Morton Ltd, Sheffield, UK)
and residual blood clots were removed. Approximately 10 g of the
minced tissue was placed in 20 ml of RPMI with 10% FCS, 4 ml
of collagenase (2 mg/ml) and 0.5 ml of DNAse (0.1 mg/ml;
Sigma) for 1 h 20 min on a roller at 37uC. After digestion, 30 ml
of RPMI 10% FCS was added and the mixture was left to stand
for 5 min to allow sedimentation. The supernatant was decanted
by aspiration and passed sequentially through 73 mm and 40 mm
filters (VWR). The filtrate was centrifuged at 400 g for 5 min and
the resulting cell pellet was re-suspended in 15 ml of PBS
supplemented with 2% FCS and 0.1% NaN3 and subsequently
overlaid onto 15 ml of Lymphoprep
TM (Axis-Shield, Oslo, Nor-
way) before further centrifugation at 710 g for 20 min with no
brake. The cells at the interface were collected; these consisted of
60–80% uNKs, 5–15% CD14
+ macrophages, 10–20% T cells as
well as stromal and epithelial cells. Cells were washed in 20 ml of
RPMI 10% FCS and centrifuged at 710 g for 5 min. CD56
bright
uNKs were removed by positive selection using CD56 antibody-
coated magnetic Microbeads as previously described[24]. The
remaining cells were transferred to a 75 cm
3 cell culture flask in
10 ml of RPMI 10 FCS and incubated at 37uC in a humidified
atmosphere of 5% CO2. After 24 h the media was changed non-
adherent cells were discarded and the adherent decidualized
stromal cells (DSCs) were allowed to attain confluence and used
for experimentation at first passage.
TGFb1 and Decidualization
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ESCs and DSCs were maintained at 37uC in 5% (v/v) CO2 in
RPMI 1640 medium (Sigma) supplemented with 2% FCS
(Mycoplex), penicillin (50 mg/ml; Sigma), streptomycin (50 mg/ml;
Sigma) and gentamycin (5 mg/ml; Sigma). The cells were seeded
in 6-well plates at a concentration of 2.5610
5 cells/ml and allowed
to adhere and attain 90% confluence. Supernatant was changed
every 3 days. Decidualization of the cells was induced in
decidualization medium (DM) consisting of RPMI 1640 medium
containing 2% FCS, 8-Bromoadenosine 39,59-cyclic monophos-
phate sodium salt (8-Br-cAMP) (0.5 mM; Sigma) and 6a-Methyl-
17a-acetoxyprogesterone (MPA) (1 mM) for 6 days. Following
decidualization cells were incubated in 2% FCS RPMI 1640 and
DM containing TGFb1 (R&D Systems, Abingdon, UK) for up to
72 h.
Targeted knockdown of SMAD 4
Two HP GenomeWide siRNA duplexes to SMAD 4 (Genbank
accession no. NM_005359) were purchased from Qiagen (Craw-
ley, United Kingdom): SMAD 4-1 (59- AAGCAGCGTCACTC-
TACCTAA), SMAD 4-2 (59- CCCTGTTAAACAGTAGT-
TGTA). An additional siRNA (Qiagen), targeting MAPK (59-
AATGCTGACTCCAAAGCTCTG) and a non-silencing control
(59-AATTCTCCGAACGTGTCACGT) were used in all exper-
iments (Qiagen). In addition, a negative control duplex (59-
AATTCTCCGAACGTGTCACGT) labelled with Alexa Fluor
488 (Qiagen) was used to monitor transfection efficiency. Cells
were transfected with siRNA duplexes using HiPerfect transfection
reagent (Qiagen). All experiments were performed in duplicate
using cells in 6-well culture dishes at 70% confluence [19]. Cells
were decidualized in vitro for 36 h, washed twice with PBS,
transfected with duplexes (5 nM) and incubated in RPMI
supplemented with 10% FCS for a further 24 h. Thereafter, cells
were treated with DM and TGFb1 (10 ng/ml) for 72 h. Following
treatment; conditioned medium was removed and analysed for
IGFBP-1 and PRL protein levels by ELISA and time-resolved
fluorimmunoassay respectively (see below). In parallel, mRNA was
prepared and analysed by Q-RT-PCR.
Taqman Quantitative Real Time PCR (Q-RT-PCR)
RNA was extracted from cells in Tri reagent (ABgene House,
Surrey, UK); RNA samples were reverse transcribed using
random hexamers. Gene-Specific Primers and Probes were
designed using Primer Express software (PerkinElmer/Applied
Biosystems, Cheshire, UK); PRL Forward: ‘5- GCCCCGGA-
GGCTATCCTA-3’, dPRL Reverse, ‘5-TCAGCTCCATGCC-
CTCTAGAA-3’, dPRL Probe ‘5-CCAAAGCTGTAGAGATT-
CAGGAGCAAACCA-3’. IGFBP-1 Forward: ‘5-CACAGGAGA-
CATCAGGAGAAGAAA-3’, IGFBP-1 Reverse: ‘5-ACACTGT-
CTGCTGTGATAAAATCCAT-3’, IGFBP-1 Probe: ‘5-TTCC-
AAATTTTACCTGCCAAACTGCAACAA-3’. Tissue Factor
Forward: 59-CAC CGA CGA GAT TGT GAA GGA-39, Tissue
Factor Reverse; 59-CCC TGC CGG GTA GGA GAA-39, Tissue
Factor Probe: 59-TGA AGC AGA CGT ACT TGG CAC GGG
T-39. Primers were diluted to 250 mM and probes to 50 mMi nT E
buffer (10 mM Tris; 1 mM EDTA in Depc H2O). PCR reaction
mixtures contained TaqManH Universal PCR Master Mix, No
AmpEraseH UNG (Applied Biosystems) (7.2 mM MgCl2; 1.6 mM
Stratagene dNTP mix; 1.6 mM Boehringer dNTP mix; 0.05 U/ml
Taq Polymerase; 2x PCR buffer and 0.06% reference dye diluted
in Depc H2O) and specific forward and reverse primers (250 nM;
Biosource, Nivelles, Belgium) and probe (50 nM; Biosource) in a
final volume of 25 ml/well. Ribosomal 18S primers and probe (PE
Biosystems, Warrington, UK) were added at a final concentration
of at 50 nM. PCR reactions were run on ABI Prism 7900 (Applied
Biosystems). Samples were measured in duplicate and mean values
were used in subsequent analysis. Relative quantification was
achieved using the formula 2
-DDCt, which relates the amount of
cDNA of the specific amplicon to the 18S internal control and the
control cDNA.
Enzyme-Linked Immunoadsorbant Assay (ELISA)
Culture supernatants were stored at 220uC. The IGFBP-1
assay used matched antibody pairs (R&D, Abingdon, Oxford) and
was conducted according to manufacturer’s protocols. Non-
decidualized and decidualized control samples were assayed in
duplicate and the concentration of IGFBP-1 was determined by
interpolation from a standard curve using known concentrations of
IGFBP-1 standards. The inter-assay variation was calculated as a
relative standard deviation and found to be 8.79% whilst intra-
assay variation was 5.98%.
Time-resolved fluorimmunoassay
Culture supernatants were stored at 220uCu n t i la s s a y e d .
Prolactin (PRL) release was measured by a DELFIAH Prolactin
time-resolved fluoroimmunoassay kit (PerkinElmer Life Sciences).
The fluoroimmunoassay was a solid phase, two-site assay based
on the direct sandwich technique. The fluorescence of each
sample is proportional to the concentration of PRL in the media
sample and was measured on a time-resolved fluorometer,
VICTOR
TM 1420 Multilevel Counter (Wallac, PerkinElmer
LAS (UK) Ltd, Beaconsfield, UK). The concentration of PRL
was determined by interpolation from a standard curve prepared
from the PRL standards. The assay was conducted according to
the manufacturer’s protocol. All samples from each experiment
were analysed in the same assay in order to preclude inter-assay
variability.
Statistical Analysis
Prior to any statistical analysis data were tested for and shown to
exhibit Gaussian distribution. Gaussian distribution was deter-
mined by applying the Shapiro-Wilk normality test to the data.
Where appropriate, values were presented as means 6 S.E.M.
Comparison of the different parameters for the various treatment
groups was determined by repeated measures analysis of variance
(ANOVA). Significant differences were assigned using Kruskal-
Wallis post hoc test. The criterion for significance for all tests was
set at p,0.05. Specific software was used to assist in the data
analysis (GraphPad Prism v4.0b for Macintosh, GraphPad
Software, San Diego, USA).
Results
TGFb1 down-regulates the production of decidualization
markers
To determine the impact of TGFb1 on decidualization, primary
human ESC (n=8, endometrial samples) were decidualized in vitro
for 6 days and then further treated with DM in the presence or
absence of TGFb1 (10 ng/ml) for 72 h. Incubation of decidua-
lized ESC with TGFb1 down-regulated the expression of IGFBP-1
mRNA in a time-dependent manner with a significant decrease
observed at 48 h (p,0.01) and 72 h (p,0.001), as compared to
time-matched controls (Figure 1A). In contrast a significant
decrease in the amount of IGFBP-1 protein released from the
cells was detected after only 2 h incubation with TGFb1 and the
amounts declined further during the rest of the experiment (12 h,
24 h, 48 h and 72 h, Figure 1B; all p,0.001). Treatment of cells
with TGFb1 was also associated with a significant decrease in
TGFb1 and Decidualization
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amount of PRL released into the culture media (Figure 1D).
Notably the patterns of expression closely paralleled those
observed for IGFBP with significant inhibition of mRNA levels
observed at 48 h (p,0.001) and 72 h (p,0.001) but a reduction in
release of PRL into the medium after only 2 h of TGFb1
treatment (p,0.05) (Figure 1D). Treatment of decidualized ESC
with TGFb1 also reduced the amount of tissue factor mRNA, with
significant suppression of mRNA levels observed at 24 h (p,0.05),
48 h (p,0.001) and 72 h (p,0.001) (Figure 1E).
Anti-TGFb1 neutralizing antibody negates TGFb1
inhibition of gene expression
hESC (n=6 endometrial samples) were decidualized in vitro for
6 days then cultured in DM in with TGFb1 (10 ng/ml) or an anti-
TGFb1 antibody (1 mg/ml) for a period of 72 h. As detailed above
incubation with TGFb1 significantly reduced the amount of PRL
(p,0.05, Figure 2A) and IGFBP-1 (p,0.001, Figure 3B) mRNAs.
We have previously demonstrated that decidualization of hESC is
associated with biosynthesis of TGFb1 [19]; in the current
experiments addition of anti-TGFb1 antibodies maintained
Figure 1. TGFb1 inhibited expression of decidualization markers when ESC were decidualized in the presence or absence of TGFb1
for up to 72 h. A: TGFb1 reduced expression of mRNA IGFBP-1 in a time dependent manner, 48 h, p,0.01, 72 h, p,0.001. 1.0= absolute value of
DCT =12. B: TGFb1 inhibited release of IGFBP-1 protein release after only 2 h of treatment (p,0.001) and this continued to decline in a time-
dependent manner (all time points p,0.001). C: TGFb1 inhibited expression of PRL mRNA in a time dependent manner, 48 h (p,0.01), 72 h
(p,0.001). 1.0= absolute value of DCT =11. D: TGFb1 inhibited PRL protein release after only 2 h of treatment (p,0.05) and this was sustained for
up to 72 h (12 h, p,0.01, 24 h, p,0.05, 48 h and 72 h, p,0.01). E: TGFb1 inhibited expression of TF mRNA in a time dependent manner; 24 h
(p,0.05), 48 h (p,0.001), 72 h (p,0.001). 1.0= absolute value of DCT =14. Data are mean 6 S.E.M; * p,0.05, ** p,0.01, *** p,0.001 vs. control.
n=8 endometrial samples (in triplicate).
doi:10.1371/journal.pone.0012970.g001
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ated expression of IGFBP-1 mRNA in comparison with ESCs
treated with DM alone (p,0.001, Figure 2B).
TGFb1 suppresses the expression and release of PRL,
IGFPB-1 and TF by cells obtained from first trimester
decidua
In order to determine whether incubation with TGFb1 had a
similar impact on primary DSC to hESC incubated in vitro, cells
were obtained from decidua recovered from pregnancies of
,10 wks gestation. Incubation with TGFb1 for up to 72 h
(n=7) resulted in a significant reduction in the amount of IGFBP-
1 mRNA (Figure 3A, p,0.05), PRL mRNA (p,0.001, Figure 3C)
and TF mRNA (p,0.05, Figure 3E) at 72 h as compared to
unstimulated, time-matched controls (Figure 3). Notably in
contrast to the results obtained with decidualized hESC incubation
of DSC with TGFb1 had no significant impact on the release of
IGFBP-1 or PRL protein (Figure 3, B and D).
TGFb1 attenuates the expression and release of PRL in a
SMAD 4-dependent manner
So as to determine whether the impact of TGFb1 on expression
and release of IGFBP-1 and PRL was mediated by the SMAD
signalling pathway, cells were transfected with SMAD 4-specific
siRNAs, a siRNA directed against MAPK (a pre-validated control
siRNA) or RNA of an unrelated sequence. Western blotting was
used to confirm .90% reduced expression of SMAD 4 (and
MAPK) in cells transfected with the sequence specific siRNAs
(data not shown). Targeted knockdown of SMAD 4 in decid-
ualized ESCs using two independent siRNAs (n=5) had no
significant impact on the TGFb1-dependent decrease in concen-
trations of IGFBP-1 mRNA (Figure 4A) and release of IGFBP-1
protein remained significantly depressed in all cells treated with
TGFb1 regardless of the addition of any of the siRNAs (Figure 4B).
In contrast, targeted knockdown of SMAD 4 prevented the
TGFb1-dependent decrease in expression of PRL mRNA
(Figure 4C) and the amount of PRL released (Figure 4D) remained
at control levels; the amount of PRL released by cells transfected
with an siRNA directed against MAPK was similar to that released
by cells incubated with TGFb1 alone.
Discussion
In the present study we have demonstrated that TGFb1 reduces
the expression and secretion of PRL, IGFBP-1, and TF by human
ESCs decidualized in vitro, as well as primary DSCs obtained from
1
st trimester decidua. Notably the latter appeared more refractory
to the treatment. Targeted knockdown of SMAD 4, the protein
which translocates phosphorylated SMAD members to the nucleus
mediating the transcriptional downstream biological actions of
TGFb1, [18] revealed that the impact of TGFb1 on expression
and release of IGFBP1was SMAD independent. In contrast
inhibition of PRL protein release was SMAD-dependent demon-
strating that TGFb1 can act via more than one signalling pathway
in this cell type.
Previous studies have reported that TGFb1 can alter expression
of decidual proteins although impacts on endometrial decidualiza-
tion have been inconsistent. To our knowledge the current study
reports the first data directly comparing the response to TGFb1i n
cells decidualized in vitro with primary cells recovered from decidua
i.e. those exposed to the presence of a blastocyst. Primary ESCs,
obtained from non-pregnant endometrium and decidualized
in vitro, are considered a model for cells that decidualize during
the non-pregnant menstrual cycle. In primary ESCs we demon-
strated incubation of cells with TGFb1 reduced both the
concentrations of IGFBP-1 and PRL mRNAs as well as the
amounts of these proteins secreted into the culture media. The
findings in the current study are in agreement with a number of
studies reporting a marked inhibitory effect of TGFb1 on basal
and stimulated PRL secretion, mRNA levels and de novo PRL
synthesis in rat anterior pituitary cells [25], decidual cells from 1
st
trimester [26] and term pregnancy [27]. However in contrast to
the current findings, it has been reported that TGFb1 can potentiate
the decidualization process in ESCs with increased production of
PRL independent of the presence of progesterone [21,22]. With a
further study reporting a TGFb1-dependent increase in expression
of PRL in ESCs [28] although these cells were not exposed to a
decidualization stimulus. One limitation to our study is that all the
Figure 2. Anti-TGFb1 antibody neutralizes endogenous TGFb1 and potentiates the decidualization process. Cultured ESCs were
decidualized in vitro in the prescence and absence of TGFb1. To confirm the specificity of the TGFb1 response anti-TGFb1 antibody (1 mg/ml) or
mouse IgG control were added, for 72 h. A: TGFb1 inhibited expression of decidual PRL (p,0.05), addition of anti-TGFb1 blocked this reduction. 1.0=
absolute value of DCT =11.5. B: TGFb1 reduced expression of IGFBP-1 mRNA (p,0.001), whilst anti-TGFb1 antibody increased expression IGFBP-1
(p,0.001) above that of controls. 1.0= absolute value of DCT =12.3. Data are mean 6 S.E.M; * p,0.05, *** p,0.001. n=6 endometrial samples (in
triplicate).
doi:10.1371/journal.pone.0012970.g002
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As we have cultured all our cells in the presence of MPA
(decidualization stimulus) we are unable to reject the possibility
that augmentation of the decidual markers is occurring as an
indirect consequence of TGFb1 mediated suppression of PR
expression [19]. Interestingly, we detected a very rapid reduction
in protein release for both IGFBP-1 and PRL in ESCs that
preceded any reduction in total concentrations of the mRNAs.
This would suggest that TGFb1 might also be repressing
translation/export of proteins or could be modulating expression
of tissue-specific microRNAs (miRNAs), short nucleotide sequenc-
es involved in post-transcriptional gene regulation that have been
implicated in endometrial function [29,30]. However, no direct
association between TGFb1 and recently identified menstruation-
specific miRNAs has been identified [31] and these suggestions
therefore remain speculative. The impact of TGFb1 on functional
activity and differentiation of ESC during the normal cycle may
also extend beyond the impact on decidualization as studies using
primary ESC reporting that TGFb1 down-regulates PR expres-
sion [19] and inhibits cell proliferation and migration [32].
Together with evidence detailing that in vivo TGFb1 expression is
increased at menstruation [33], and TGFb1 can induce contrac-
Figure 3. TGFb1 suppresses expression and release of markers of decidualization by cells from 1
st trimester decidua. A: TGFb1
reduced expression of IGFBP-1 mRNA after 72 h treatment. (p,0.05) 1.0= absolute value of DCT =12.2. B: TGFb1 was without significant effect on
protein release of IGFBP-1. C: TGFb1 reduced expression of PRL mRNA after 72 h treatment (p,0.001). 1.0= absolute value of DCT =11.5. D: TGFb1
was without significant effect on PRL protein release, although did display a trend toward inhibition. E: TGFb1 reduced expression of TF mRNA after
72 h treatment (p,0.05). 1.0= absolute value of DCT =13.75. Data are mean 6 S.E.M; * p,0.05, *** p,0.001 vs. no TGFb1 treatment. n=7 decidual
samples (in triplicate).
doi:10.1371/journal.pone.0012970.g003
TGFb1 and Decidualization
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TGFb1 may play a role in the onset of menstruation in normal
cycling endometrium. Furthermore, aberrant expression of
TGFb1 may contribute to menstrual disorders, such as heavy
menstrual bleeding and painful menstruation, by modifying local
haemostatic mechanisms (reviewed in [35]).
To determine if decidualized stromal cells would respond to
TGFb1 in the same manner as primary ESCs that were
decidualized in vitro, we isolated stromal cells from first trimester
decidua. Although, the present studies have demonstrated that
TGFb1 markedly inhibits the expression of PRL, IGFBP-1, and
TF mRNAs in DSCs this inhibition was delayed by at least 24 h
when compared to the response observed in ESC. Furthermore,
this inhibitory effect at the level of mRNA was not reflected by a
reduction in mature protein secretion of PRL and IGFBP-1 by
DSC, implying that decidualization in vivo, confers some resistance
to the actions of TGFb1. The findings in the current study are in
agreement with studies reporting that TGFb1 inhibited both
IGFBP-1 and PRL production in a time-dependent manner in
decidual cells from 1
st trimester [26,36] and term pregnancy [27].
However, the effect of TGFb1 on PR expression in DSCs remains
unknown making it difficult to interpret the results in terms of
direct effects of TGFb1 on DSCs as opposed to an indirect effect
via suppression of PR [19]. It may be that the presence of a
blastocyst and increasing concentrations of hCG in the first
trimester of pregnancy evokes an increase in cellular protection
against potentially harmful cytokines and growth factors. Alterna-
tively, the role of TGFb1 in pregnant endometrium could differ
Figure 4. TGFb1 attenuates expression and release of prolactin in a SMAD-dependent manner. Incubation with TGFb1 (10 ng/ml; 72 h)
significantly reduced expression of mRNAs encoding IGFBP-1 and PRL (p,0.001 IGFBP1; graph A 1.0= absolute value of DCT =12.2, p,0.05 PRL;
graph C 1.0= absolute value of DCT =11) and the amount of each of these proteins recovered from culture media (p,0.001 IGFBP1, graph B, p,0.01
PRL, graph D) after incubation of decidualized ESCs for 72 h. Depletion of SMAD 4 using two independent target-specific siRNAs had no significant
impact on the TGFb1-dependent reduction in IGFBP-1 mRNA or protein (graphs A 1.0= absolute value of DCT =12.2, B) but reversed the reduction in
PRL mRNA (p,0.001, graph C 1.0= absolute value of DCT =11.25) and protein (p,0.01, graph D) induced by treatment. No response was observed
with cells depleted of MAPK siRNA. Data are mean 6 S.E.M; * p,0.05, ** p,0.01, *** p,0.001 vs. TGFb1 alone. n=5 endometrial samples (in
triplicate).
doi:10.1371/journal.pone.0012970.g004
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is supported by data reporting high expression of TGFb1 in first
trimester decidua without any detrimental effect on pregnancy
[37,38,39]. Aberrant increases in active TGFb1 during early
pregnancy may be detrimental as a consequence of inadequate
decidualization of the endometrium.
To determine if TGFb1 was conferring its actions via its
canonical signalling cascade we interrogated the common
mediator of all SMAD signal transduction, SMAD 4 [40]. We
have demonstrated via knockdown of SMAD 4 that TGFb1-
induced suppression of IGFBP-1 is not SMAD-dependent and
these data suggest that TGFb1 is mediating its effects via an
alternative pathway or an indirect mechanism, as has been
suggested previously [41]. This may include the involvement of
Wnt signalling pathways as previous reports have shown that
progesterone-dependent changes in expression of the Wnt
antagonist DKK parallel changes in secretion of IGFBP-1 protein
[42]. This report was complemented by our own study
demonstrating that TGFb1 inhibits expression of DKK-1 mRNA
in a SMAD-independent manner [19]. In contrast TGFb1-specific
down regulation of expression of PRL was SMAD-dependent and
the impact of TGFb1 was reversed in cells transfected with
SMAD-4 specific si-RNAs. This finding would be consistent with
previous reports demonstrating that activin-dependent inhibition
of expression of PRL in the pituitary is mediated by the SMAD
signalling pathway [43]. Other studies reporting conflicting results
to our own have also demonstrated a role for SMAD signalling in
propagating TGFb1 actions [22,28], with the authors claiming
that both ERK and SMAD dependent signalling may play a role
in the TGFb1-dependent increase in expression of PRL in ESC
[28]. However, in contrast, the impact of TGFb1 in our
decidualized cells appeared to be independent of expression of
MAPK. It is likely that TGFb1 may be evoking responses in genes
that are not normally associated with decidualization e.g induction
of smooth muscle actin a (Kane et al, unpublished observations);
however genome-wide transcriptional profiling is beyond the
scope of this research.
In summary, the findings presented in the current study have
demonstrated that TGFb1 is capable of suppressing expression
and secretion of decidualization marker proteins via both SMAD-
dependent and independent mechanisms. Our findings support
the hypothesis that local TGFb1 signalling may coordinate de-
differentiation of endometrial stromal compartment and tissue
remodelling associated with menstruation, but raise the possibility
that this factor may play a different role in the pregnant
endometrium.
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